-
B288192-10mgBW B70C has been used as a 5-lipoxygenase inhibitor to study its effects on eryptosis in erythrocytes.
-
B288192-25mgBW B70C has been used as a 5-lipoxygenase inhibitor to study its effects on eryptosis in erythrocytes.
-
B288192-50mgBW B70C has been used as a 5-lipoxygenase inhibitor to study its effects on eryptosis in erythrocytes.
-
B288192-5mgBW B70C has been used as a 5-lipoxygenase inhibitor to study its effects on eryptosis in erythrocytes.
-
B287874-100mgATP synthase inhibitor: proapoptotic.
-
B287874-10mgATP synthase inhibitor: proapoptotic.
-
B287874-25mgATP synthase inhibitor: proapoptotic.
-
B287874-50mgATP synthase inhibitor: proapoptotic.
-
B287874-5mgATP synthase inhibitor: proapoptotic.
-
C409469-1mlExtinction Coeff.A280 nm = 0.89 at 1.0 mg/mL for pure C1Protein Purity>:95% by SDS PageGeneral DescriptionC1 is the first complement component in the cascade referred to as the classical pathway of complement. C1 binds to and is activated by
-
C414547-1000μgProtein Purity>:95 % by SDS PAGEExtinction Coeff.A280 nm = 0.45 at 1.0 mg/mLMolecular Weight110,000 Da (single chain)General DescriptionThe protease inhibitor C1-INH prevents the spontaneous activation of complement and limits consumption of C2
-
C409490-1000μgExtinction Coeff.A280 nm = 0.68 at 1.0 mg/ml for pure C1qProtein Purity>: 98% by SDS PAGMolecular Weight410,000 Da (18 chains)General DescriptionC1q separated from C1r and C1s and from other stabilizing proteins tends to aggregate easily. Because